<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065336</url>
  </required_header>
  <id_info>
    <org_study_id>Heparc-2001</org_study_id>
    <nct_id>NCT02065336</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection, Followed by a Two-dose Open-label Cohort and Three Open-label Single-dose Cohorts in Treatment Naïve Patients, Including a Multi-dose Open-label Extension at a Single Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ARC-520 in combination with entecavir is
      effective in the treatment of patients with chronic HBV Infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with ARC-520 for injection is expected to reduce all HBV proteins and replicative
      intermediates via ribonucleic acid (RNA) interference. The magnitude of the reduction and
      duration of effect will depend on the dose. Since to date ARC-520 has not been administered
      to patients with chronic HBV infection, the effective therapeutic dose in patients with
      chronic HBV infection is unknown. This study is designed to assess the antiviral activity of
      ARC-520, especially its effect on HBsAg, in patients with chronic HBV infection at different
      dose levels.

      This is a multicenter, randomized, double-blind, placebo-controlled, single-dose escalation
      study of ARC 520 in combination with entecavir administered to participants with hepatitis B
      virus e antigen (HBeAg)-negative (Cohorts 1 through 4) or HBeAg-positive (Cohort 5) immune
      active, chronic HBV infection, followed by a two-dose open-label cohort (Cohort 6), three
      open-label single-dose cohorts in treatment-naïve participants (Cohorts 7, 11 and 12) and an
      open-label multi-dose extension study (Cohorts 8, 9, 10). Cohort 6 will investigate ARC-520
      in combination with entecavir administered in two doses to participants with HBeAg-positive
      immune-active chronic HBV infection. Cohorts 7, 11 and 12 will enroll treatment-naïve
      participants. Cohort 8 will only enroll participants previously completing Cohorts 1-4.
      Cohort 9 will only enroll participants previously completing Cohort 5 or 6. Cohort 10 will
      only enroll participants previously completing Cohort 7.

      Participants will undergo the following evaluations at regular intervals during the study:
      medical history, physical examinations, vital sign measurements (blood pressure, heart rate,
      respiratory rate, and temperature), weight, adverse events (AEs), 12-lead electrocardiograms
      (ECGs), concomitant medication, blood sample collection for hematology, coagulation,
      chemistry, pharmacokinetic (PK) and exploratory pharmacodynamic (PD) measures, urinalysis,
      HBV serology, HBV genotyping and sequencing, follicle stimulating hormone (FSH) testing and
      pregnancy testing for females of childbearing potential. Clinically significant changes
      including AEs will be followed until resolution, until the condition stabilizes, until the
      event is otherwise explained, or until the participant is lost to follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to discontinue trial
  </why_stopped>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)</measure>
    <time_frame>Baseline, through Day 85 (Cohorts 1-7) and through 24 weeks post-last dose (last dose: Day 85 Cohort 9; Day 253 Cohort 10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>through Day 85 (Cohorts 1-7) and through 24 weeks post-last dose (last dose: Day 85 Cohort 9; Day 225 Cohort 10)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. An SAE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Negative Bee Venom Allergy Test Results at Baseline, Day 29, and Day 85</measure>
    <time_frame>Baseline, Day 29, Day 85</time_frame>
    <description>Bee venom allergy tests were used to assess immunoglobulin E (IgE) in Cohorts 1-7. Analysis values less than 0.35 kU/L were taken as negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Entecavir Plasma Trough Concentration, Cohorts 1-7</measure>
    <time_frame>Baseline, Days 1, 2, 3, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Cohorts 1-5 Only</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Maximum Observed Plasma Concentration (Cmax), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Clearance (CL), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Apparent Volume of Distribution During the Terminal Phase (Vz), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Volume in Steady State (Vss), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Rate Constant (Kel), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Half-Life (t1/2), Cohorts 1-5</measure>
    <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Normal Saline Cohorts 1-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every [Q]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-520</intervention_name>
    <arm_group_label>ARC-520 Cohort 1</arm_group_label>
    <arm_group_label>ARC-520 Cohort 10</arm_group_label>
    <arm_group_label>ARC-520 Cohort 11</arm_group_label>
    <arm_group_label>ARC-520 Cohort 12</arm_group_label>
    <arm_group_label>ARC-520 Cohort 2</arm_group_label>
    <arm_group_label>ARC-520 Cohort 3</arm_group_label>
    <arm_group_label>ARC-520 Cohort 4</arm_group_label>
    <arm_group_label>ARC-520 Cohort 5</arm_group_label>
    <arm_group_label>ARC-520 Cohort 6</arm_group_label>
    <arm_group_label>ARC-520 Cohort 7</arm_group_label>
    <arm_group_label>ARC-520 Cohort 8</arm_group_label>
    <arm_group_label>ARC-520 Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Normal Saline Cohorts 1-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <arm_group_label>ARC-520 Cohort 1</arm_group_label>
    <arm_group_label>ARC-520 Cohort 2</arm_group_label>
    <arm_group_label>ARC-520 Cohort 3</arm_group_label>
    <arm_group_label>ARC-520 Cohort 4</arm_group_label>
    <arm_group_label>ARC-520 Cohort 5</arm_group_label>
    <arm_group_label>ARC-520 Cohort 8</arm_group_label>
    <arm_group_label>ARC-520 Cohort 9</arm_group_label>
    <arm_group_label>Placebo Normal Saline Cohorts 1-5</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorpheniramine</intervention_name>
    <description>In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.</description>
    <arm_group_label>ARC-520 Cohort 1</arm_group_label>
    <arm_group_label>ARC-520 Cohort 10</arm_group_label>
    <arm_group_label>ARC-520 Cohort 11</arm_group_label>
    <arm_group_label>ARC-520 Cohort 12</arm_group_label>
    <arm_group_label>ARC-520 Cohort 2</arm_group_label>
    <arm_group_label>ARC-520 Cohort 3</arm_group_label>
    <arm_group_label>ARC-520 Cohort 4</arm_group_label>
    <arm_group_label>ARC-520 Cohort 5</arm_group_label>
    <arm_group_label>ARC-520 Cohort 6</arm_group_label>
    <arm_group_label>ARC-520 Cohort 7</arm_group_label>
    <arm_group_label>ARC-520 Cohort 8</arm_group_label>
    <arm_group_label>ARC-520 Cohort 9</arm_group_label>
    <arm_group_label>Placebo Normal Saline Cohorts 1-5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of HBeAg negative and immune active chronic HBV infection (Cohorts 1-4, 8)

          -  Diagnosis of HBeAg positive and immune active chronic HBV infection (Cohorts 5-6, 9)

          -  Diagnosis of HBeAg negative or HBeAg positive and immune active or tolerant chronic
             HBV infection (Cohorts 7, 10, 11 &amp; 12)

          -  Patients with &gt; 6 months of continuous, 0.5 mg/day oral entecavir, and a willingness
             to continue taking entecavir throughout the study (Cohorts 1-6, 8-9).

          -  Patients naive to entecavir (never on entecavir or on entecavir &lt;30 days prior to
             screening) and a willingness to take entecavir and willingness to continue taking
             entecavir throughout the study (Cohorts 7, 11 &amp; 12).

        Key Exclusion Criteria:

          -  Female patients that have a positive pregnancy test or are lactating.

          -  Acute signs of hepatitis/other infection (eg, moderate fever, jaundice, nausea,
             vomiting, and abdominal pain) evident within 4 weeks of screening and/or at the
             screening examination.

          -  Patients with antiviral therapy other than entecavir within 3 months of screening or
             prior treatment with interferon or a toll receptor agonist in the last 5 years.

          -  Use within the last 6 months or an anticipated requirement for anticoagulants,
             corticosteroids, immunomodulators, or immunosuppressants.

          -  Has any history of autoimmune disease especially autoimmune hepatitis.

          -  Has human immunodeficiency virus (HIV) infection, as shown by the presence of anti-HIV
             antibody (sero-positive).

          -  Is sero-positive for hepatitis C virus (HCV), and/or a history of delta virus
             hepatitis.

          -  Has a history of allergy to bee venom or history of hypersensitivity reaction
             requiring an emergency visit to a physician or hospital and/or requirement for
             treatment with steroids and/or epinephrine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Given, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arrowhead Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>January 10, 2018</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpheniramine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No patients were enrolled in Cohorts 8, 11, or 12. Cohort 9 (n=2) and Cohort 10 (n=8) enrolled participants who previously completed treatment in other cohorts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ARC-520 Cohort 1</title>
          <description>a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="P2">
          <title>ARC-520 Cohort 2</title>
          <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="P3">
          <title>ARC-520 Cohort 3</title>
          <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="P4">
          <title>ARC-520 Cohort 4</title>
          <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="P5">
          <title>ARC-520 Cohort 5</title>
          <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
        </group>
        <group group_id="P6">
          <title>ARC-520 Cohort 6</title>
          <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV</description>
        </group>
        <group group_id="P7">
          <title>ARC-520 Cohort 7</title>
          <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)</description>
        </group>
        <group group_id="P8">
          <title>Placebo Normal Saline Cohorts 1-5</title>
          <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
        </group>
        <group group_id="P9">
          <title>ARC-520 Cohort 9</title>
          <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6</description>
        </group>
        <group group_id="P10">
          <title>ARC-520 Cohort 10</title>
          <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARC-520 Cohort 1</title>
          <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="B2">
          <title>ARC-520 Cohort 2</title>
          <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="B3">
          <title>ARC-520 Cohort 3</title>
          <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="B4">
          <title>ARC-520 Cohort 4</title>
          <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="B5">
          <title>ARC-520 Cohort 5</title>
          <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
        </group>
        <group group_id="B6">
          <title>ARC-520 Cohort 6</title>
          <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV</description>
        </group>
        <group group_id="B7">
          <title>ARC-520 Cohort 7</title>
          <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)</description>
        </group>
        <group group_id="B8">
          <title>Placebo Normal Saline Cohorts 1-5</title>
          <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="8.22"/>
                    <measurement group_id="B2" value="43.0" spread="4.15"/>
                    <measurement group_id="B3" value="42.0" spread="1.79"/>
                    <measurement group_id="B4" value="39.8" spread="2.04"/>
                    <measurement group_id="B5" value="39.5" spread="7.23"/>
                    <measurement group_id="B6" value="33.3" spread="4.23"/>
                    <measurement group_id="B7" value="39.8" spread="10.12"/>
                    <measurement group_id="B8" value="44.4" spread="9.09"/>
                    <measurement group_id="B9" value="41.4" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)</title>
        <time_frame>Baseline, through Day 85 (Cohorts 1-7) and through 24 weeks post-last dose (last dose: Day 85 Cohort 9; Day 253 Cohort 10)</time_frame>
        <population>Pharmacodynamic (PD) Population: all participants who received at least 1 dose of study drug and had evaluable data from at least one postdose PD assessment according to the treatment the participants were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
          <group group_id="O6">
            <title>ARC-520 Cohort 6</title>
            <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV</description>
          </group>
          <group group_id="O7">
            <title>ARC-520 Cohort 7</title>
            <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Normal Saline Cohorts 1-5</title>
            <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
          </group>
          <group group_id="O9">
            <title>ARC-520 Cohort 9</title>
            <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6</description>
          </group>
          <group group_id="O10">
            <title>ARC-520 Cohort 10</title>
            <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)</title>
          <population>Pharmacodynamic (PD) Population: all participants who received at least 1 dose of study drug and had evaluable data from at least one postdose PD assessment according to the treatment the participants were assigned.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-19222" spread="27217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-554.8" spread="861.86"/>
                    <measurement group_id="O2" value="-1194.0" spread="2083.72"/>
                    <measurement group_id="O3" value="-1003.6" spread="949.36"/>
                    <measurement group_id="O4" value="-1501.0" spread="1930.12"/>
                    <measurement group_id="O5" value="-1664.7" spread="2375.62"/>
                    <measurement group_id="O6" value="-948.0" spread="1016.31"/>
                    <measurement group_id="O7" value="-12401.1" spread="17661.02"/>
                    <measurement group_id="O8" value="43.3" spread="267.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-928.1" spread="1285.26"/>
                    <measurement group_id="O2" value="-2179.2" spread="3170.68"/>
                    <measurement group_id="O3" value="-884.3" spread="1296.49"/>
                    <measurement group_id="O4" value="-2591.2" spread="3304.72"/>
                    <measurement group_id="O5" value="-1789.8" spread="2101.23"/>
                    <measurement group_id="O6" value="-1344.0" spread="1319.66"/>
                    <measurement group_id="O7" value="-20123.8" spread="29795.99"/>
                    <measurement group_id="O8" value="42.2" spread="568.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1055.1" spread="1900.89"/>
                    <measurement group_id="O2" value="-2260.8" spread="4022.82"/>
                    <measurement group_id="O3" value="-470.8" spread="2025.31"/>
                    <measurement group_id="O4" value="-3069.0" spread="3923.45"/>
                    <measurement group_id="O5" value="-1672.8" spread="1892.73"/>
                    <measurement group_id="O7" value="-22915.6" spread="34381.59"/>
                    <measurement group_id="O8" value="236.6" spread="321.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1225.4" spread="1967.15"/>
                    <measurement group_id="O2" value="-2266.2" spread="3868.90"/>
                    <measurement group_id="O3" value="-204.3" spread="2077.12"/>
                    <measurement group_id="O4" value="-2978.8" spread="3536.73"/>
                    <measurement group_id="O5" value="-1951.7" spread="2819.85"/>
                    <measurement group_id="O6" value="-1553.7" spread="1596.05"/>
                    <measurement group_id="O7" value="-23872.7" spread="35753.39"/>
                    <measurement group_id="O8" value="115.1" spread="594.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-579.1" spread="352.71"/>
                    <measurement group_id="O2" value="-1826.3" spread="2618.78"/>
                    <measurement group_id="O3" value="93.3" spread="2425.68"/>
                    <measurement group_id="O4" value="-2972.8" spread="3506.01"/>
                    <measurement group_id="O5" value="-1964.3" spread="2501.62"/>
                    <measurement group_id="O6" value="-1532.3" spread="1500.40"/>
                    <measurement group_id="O7" value="-24148.3" spread="36256.02"/>
                    <measurement group_id="O8" value="168.8" spread="460.59"/>
                    <measurement group_id="O10" value="-22617" spread="32653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1020.1" spread="1252.98"/>
                    <measurement group_id="O2" value="-1288.8" spread="1498.60"/>
                    <measurement group_id="O3" value="-1471.8" spread="1625.30"/>
                    <measurement group_id="O4" value="-3219.8" spread="3601.70"/>
                    <measurement group_id="O5" value="-1939.7" spread="2277.79"/>
                    <measurement group_id="O6" value="-1566.8" spread="1290.46"/>
                    <measurement group_id="O7" value="-23932.0" spread="35929.80"/>
                    <measurement group_id="O8" value="58.3" spread="411.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1056.7" spread="773.69"/>
                    <measurement group_id="O3" value="-2330.1" spread="1676.50"/>
                    <measurement group_id="O4" value="-2813.0" spread="2665.97"/>
                    <measurement group_id="O5" value="-1536.0" spread="1373.46"/>
                    <measurement group_id="O6" value="-1370.7" spread="872.64"/>
                    <measurement group_id="O7" value="-22658.4" spread="34292.84"/>
                    <measurement group_id="O8" value="156.1" spread="527.40"/>
                    <measurement group_id="O10" value="-22840" spread="32239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-670.1" spread="1825.99"/>
                    <measurement group_id="O2" value="-542.8" spread="1815.34"/>
                    <measurement group_id="O3" value="-2119.3" spread="1717.17"/>
                    <measurement group_id="O4" value="-926.3" spread="1406.29"/>
                    <measurement group_id="O5" value="-537.5" spread="1901.16"/>
                    <measurement group_id="O6" value="-791.0" spread="457.04"/>
                    <measurement group_id="O7" value="-20827.2" spread="31753.76"/>
                    <measurement group_id="O8" value="225.4" spread="393.81"/>
                    <measurement group_id="O10" value="-23305" spread="32455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-23205" spread="32362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-23182" spread="32379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-26481" spread="33649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-30234" spread="34097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-1249" spread="1273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O10" value="-643" spread="905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. An SAE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
        <time_frame>through Day 85 (Cohorts 1-7) and through 24 weeks post-last dose (last dose: Day 85 Cohort 9; Day 225 Cohort 10)</time_frame>
        <population>Safety Population: all participants who received any amount of study drug or placebo, and had at least 1 postdose safety assessment. Data for Cohort 9 was not analyzed or summarized due to limited enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
          <group group_id="O6">
            <title>ARC-520 Cohort 6</title>
            <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV</description>
          </group>
          <group group_id="O7">
            <title>ARC-520 Cohort 7</title>
            <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with CHB</description>
          </group>
          <group group_id="O8">
            <title>ARC-520 Cohort 9</title>
            <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6</description>
          </group>
          <group group_id="O9">
            <title>ARC-520 Cohort 10</title>
            <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7</description>
          </group>
          <group group_id="O10">
            <title>Placebo Normal Saline Cohorts 1-5</title>
            <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. An SAE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
          <population>Safety Population: all participants who received any amount of study drug or placebo, and had at least 1 postdose safety assessment. Data for Cohort 9 was not analyzed or summarized due to limited enrollment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any mild TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any moderate TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to discontinuation of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any life-threatening SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Negative Bee Venom Allergy Test Results at Baseline, Day 29, and Day 85</title>
        <description>Bee venom allergy tests were used to assess immunoglobulin E (IgE) in Cohorts 1-7. Analysis values less than 0.35 kU/L were taken as negative.</description>
        <time_frame>Baseline, Day 29, Day 85</time_frame>
        <population>Safety Population: all participants who received any amount of study drug or placebo, and had at least 1 postdose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
          <group group_id="O6">
            <title>ARC-520 Cohort 6</title>
            <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune-active chronic HBV</description>
          </group>
          <group group_id="O7">
            <title>ARC-520 Cohort 7</title>
            <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with CHB</description>
          </group>
          <group group_id="O8">
            <title>Placebo Normal Saline Cohorts 1-5</title>
            <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Negative Bee Venom Allergy Test Results at Baseline, Day 29, and Day 85</title>
          <description>Bee venom allergy tests were used to assess immunoglobulin E (IgE) in Cohorts 1-7. Analysis values less than 0.35 kU/L were taken as negative.</description>
          <population>Safety Population: all participants who received any amount of study drug or placebo, and had at least 1 postdose safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Entecavir Plasma Trough Concentration, Cohorts 1-7</title>
        <time_frame>Baseline, Days 1, 2, 3, 8, 15, 22, 29</time_frame>
        <population>Pharmacokinetic (PK) Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohorts 4 and 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection or participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 6</title>
            <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune-active chronic HBV</description>
          </group>
          <group group_id="O6">
            <title>ARC-520 Cohort 7</title>
            <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with CHB</description>
          </group>
          <group group_id="O7">
            <title>Placebo Normal Saline Cohorts 1-5</title>
            <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Entecavir Plasma Trough Concentration, Cohorts 1-7</title>
          <population>Pharmacokinetic (PK) Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.05"/>
                    <measurement group_id="O2" value="0.06" spread="0.08"/>
                    <measurement group_id="O3" value="0.13" spread="0.08"/>
                    <measurement group_id="O4" value="0.12" spread="0.10"/>
                    <measurement group_id="O5" value="-0.91" spread="1.59"/>
                    <measurement group_id="O6" value="0.16" spread="0.04"/>
                    <measurement group_id="O7" value="-0.31" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.02"/>
                    <measurement group_id="O2" value="-0.06" spread="0.09"/>
                    <measurement group_id="O3" value="-0.06" spread="0.06"/>
                    <measurement group_id="O4" value="0.12" spread="0.63"/>
                    <measurement group_id="O5" value="-1.04" spread="1.58"/>
                    <measurement group_id="O6" value="0.15" spread="0.03"/>
                    <measurement group_id="O7" value="-0.29" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.07"/>
                    <measurement group_id="O2" value="-0.09" spread="0.08"/>
                    <measurement group_id="O3" value="-0.09" spread="0.13"/>
                    <measurement group_id="O4" value="-0.03" spread="0.18"/>
                    <measurement group_id="O5" value="-1.01" spread="1.60"/>
                    <measurement group_id="O6" value="0.45" spread="0.76"/>
                    <measurement group_id="O7" value="-0.30" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.05"/>
                    <measurement group_id="O2" value="-0.03" spread="0.12"/>
                    <measurement group_id="O3" value="-0.03" spread="0.06"/>
                    <measurement group_id="O4" value="0.00" spread="0.18"/>
                    <measurement group_id="O5" value="-1.01" spread="1.63"/>
                    <measurement group_id="O6" value="0.32" spread="0.11"/>
                    <measurement group_id="O7" value="-0.10" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.06"/>
                    <measurement group_id="O2" value="-0.02" spread="0.14"/>
                    <measurement group_id="O3" value="-0.03" spread="0.09"/>
                    <measurement group_id="O4" value="0.00" spread="0.13"/>
                    <measurement group_id="O5" value="-1.00" spread="1.58"/>
                    <measurement group_id="O6" value="0.33" spread="0.11"/>
                    <measurement group_id="O7" value="-0.30" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.06"/>
                    <measurement group_id="O2" value="-0.01" spread="0.11"/>
                    <measurement group_id="O3" value="0.01" spread="0.07"/>
                    <measurement group_id="O4" value="0.00" spread="0.15"/>
                    <measurement group_id="O5" value="-1.00" spread="1.61"/>
                    <measurement group_id="O6" value="0.36" spread="0.11"/>
                    <measurement group_id="O7" value="-0.30" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" spread="8.28"/>
                    <measurement group_id="O2" value="185" spread="61.2"/>
                    <measurement group_id="O3" value="212" spread="34.7"/>
                    <measurement group_id="O4" value="318" spread="82.3"/>
                    <measurement group_id="O5" value="349" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" spread="9.11"/>
                    <measurement group_id="O2" value="190" spread="43.2"/>
                    <measurement group_id="O3" value="301" spread="43.9"/>
                    <measurement group_id="O4" value="370" spread="80.5"/>
                    <measurement group_id="O5" value="412" spread="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="9.25"/>
                    <measurement group_id="O2" value="196" spread="66.3"/>
                    <measurement group_id="O3" value="218" spread="37.1"/>
                    <measurement group_id="O4" value="326" spread="87.3"/>
                    <measurement group_id="O5" value="356" spread="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="9.77"/>
                    <measurement group_id="O2" value="205" spread="50.2"/>
                    <measurement group_id="O3" value="317" spread="50.7"/>
                    <measurement group_id="O4" value="385" spread="88.0"/>
                    <measurement group_id="O5" value="434" spread="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Cohorts 1-5 Only</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Cohorts 1-5 Only</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="9.26"/>
                    <measurement group_id="O2" value="196" spread="66.3"/>
                    <measurement group_id="O3" value="218" spread="37.2"/>
                    <measurement group_id="O4" value="326" spread="87.4"/>
                    <measurement group_id="O5" value="356" spread="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" spread="9.80"/>
                    <measurement group_id="O2" value="207" spread="51.1"/>
                    <measurement group_id="O3" value="318" spread="51.2"/>
                    <measurement group_id="O4" value="386" spread="88.6"/>
                    <measurement group_id="O5" value="435" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Maximum Observed Plasma Concentration (Cmax), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Maximum Observed Plasma Concentration (Cmax), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="2.42"/>
                    <measurement group_id="O2" value="26.4" spread="6.84"/>
                    <measurement group_id="O3" value="33.5" spread="1.78"/>
                    <measurement group_id="O4" value="54.8" spread="9.59"/>
                    <measurement group_id="O5" value="58.2" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="2.07"/>
                    <measurement group_id="O2" value="22.5" spread="2.74"/>
                    <measurement group_id="O3" value="39.7" spread="2.60"/>
                    <measurement group_id="O4" value="50.5" spread="10.6"/>
                    <measurement group_id="O5" value="52.4" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Clearance (CL), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Clearance (CL), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>mL/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="0.724"/>
                    <measurement group_id="O2" value="5.58" spread="1.84"/>
                    <measurement group_id="O3" value="7.11" spread="1.56"/>
                    <measurement group_id="O4" value="6.47" spread="1.51"/>
                    <measurement group_id="O5" value="5.70" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="0.522"/>
                    <measurement group_id="O2" value="5.08" spread="1.19"/>
                    <measurement group_id="O3" value="4.84" spread="0.952"/>
                    <measurement group_id="O4" value="5.41" spread="1.19"/>
                    <measurement group_id="O5" value="4.65" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Apparent Volume of Distribution During the Terminal Phase (Vz), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Apparent Volume of Distribution During the Terminal Phase (Vz), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="4.13"/>
                    <measurement group_id="O2" value="43.2" spread="15.8"/>
                    <measurement group_id="O3" value="45.7" spread="5.72"/>
                    <measurement group_id="O4" value="39.0" spread="7.27"/>
                    <measurement group_id="O5" value="35.4" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="5.01"/>
                    <measurement group_id="O2" value="46.1" spread="9.99"/>
                    <measurement group_id="O3" value="37.1" spread="2.52"/>
                    <measurement group_id="O4" value="37.9" spread="5.83"/>
                    <measurement group_id="O5" value="36.9" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Volume in Steady State (Vss), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Volume in Steady State (Vss), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="6.05"/>
                    <measurement group_id="O2" value="45.8" spread="11.6"/>
                    <measurement group_id="O3" value="45.3" spread="3.60"/>
                    <measurement group_id="O4" value="39.6" spread="6.31"/>
                    <measurement group_id="O5" value="35.3" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="6.01"/>
                    <measurement group_id="O2" value="46.7" spread="8.22"/>
                    <measurement group_id="O3" value="38.1" spread="2.08"/>
                    <measurement group_id="O4" value="39.8" spread="6.36"/>
                    <measurement group_id="O5" value="38.5" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Rate Constant (Kel), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Rate Constant (Kel), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157" spread="0.0115"/>
                    <measurement group_id="O2" value="0.132" spread="0.0242"/>
                    <measurement group_id="O3" value="0.154" spread="0.0135"/>
                    <measurement group_id="O4" value="0.165" spread="0.0120"/>
                    <measurement group_id="O5" value="0.161" spread="0.00614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.0131"/>
                    <measurement group_id="O2" value="0.111" spread="0.0188"/>
                    <measurement group_id="O3" value="0.130" spread="0.0180"/>
                    <measurement group_id="O4" value="0.142" spread="0.0164"/>
                    <measurement group_id="O5" value="0.126" spread="0.00793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Half-Life (t1/2), Cohorts 1-5</title>
        <time_frame>Day 1 predose, immediately prior to the end of infusion, 0.5, 1, 3, 6, 24, and 48 hours postdose</time_frame>
        <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>ARC-520 Cohort 1</title>
            <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O2">
            <title>ARC-520 Cohort 2</title>
            <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O3">
            <title>ARC-520 Cohort 3</title>
            <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O4">
            <title>ARC-520 Cohort 4</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
          </group>
          <group group_id="O5">
            <title>ARC-520 Cohort 5</title>
            <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Half-Life (t1/2), Cohorts 1-5</title>
          <population>PK Population: all participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AD0009</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" lower_limit="4.06" upper_limit="4.96"/>
                    <measurement group_id="O2" value="5.36" lower_limit="4.16" upper_limit="7.00"/>
                    <measurement group_id="O3" value="4.64" lower_limit="3.87" upper_limit="4.90"/>
                    <measurement group_id="O4" value="4.18" lower_limit="3.92" upper_limit="4.87"/>
                    <measurement group_id="O5" value="4.32" lower_limit="4.14" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD0010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" lower_limit="4.76" upper_limit="6.19"/>
                    <measurement group_id="O2" value="6.32" lower_limit="5.09" upper_limit="7.94"/>
                    <measurement group_id="O3" value="5.48" lower_limit="4.26" upper_limit="6.41"/>
                    <measurement group_id="O4" value="4.79" lower_limit="4.32" upper_limit="6.15"/>
                    <measurement group_id="O5" value="5.36" lower_limit="5.16" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug through Day 85 (Cohorts 1-7) and through 24 weeks post-last dose (last dose: Day 85 Cohort 9; Day 225 Cohort 10)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARC-520 Cohort 1</title>
          <description>a single IV dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="E2">
          <title>ARC-520 Cohort 2</title>
          <description>a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="E3">
          <title>ARC-520 Cohort 3</title>
          <description>a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="E4">
          <title>ARC-520 Cohort 4</title>
          <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection</description>
        </group>
        <group group_id="E5">
          <title>ARC-520 Cohort 5</title>
          <description>a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection</description>
        </group>
        <group group_id="E6">
          <title>ARC-520 Cohort 6</title>
          <description>two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune-active chronic HBV</description>
        </group>
        <group group_id="E7">
          <title>ARC-520 Cohort 7</title>
          <description>a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with CHB</description>
        </group>
        <group group_id="E8">
          <title>ARC-520 Cohort 9</title>
          <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6</description>
        </group>
        <group group_id="E9">
          <title>ARC-520 Cohort 10</title>
          <description>open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7</description>
        </group>
        <group group_id="E10">
          <title>Placebo Normal Saline Cohorts 1-5</title>
          <description>a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The ARC-520 Injection development program was terminated early for regulatory and business reasons secondary to findings occurring in a non-clinical toxicology study. Program termination was not due to safety findings in humans.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Operating Officer</name_or_title>
      <organization>Arrowhead Pharmaceuticals, Inc.</organization>
      <phone>626-304-3400</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

